Alexander Alfano

I'll research this attorney before drafting.

Alexander Alfano — Patent Litigation Practice Summary

Focus areas. Alfano's practice centers on life-sciences patent litigation: Hatch-Waxman/ANDA Paragraph IV disputes over small-molecule and biologic drugs, plus biotechnology, diagnostics, and medical devices. Firm bios describe his work as patent litigation and counseling with a substantial FDA-regulatory overlay — Orange Book listing and patent certifications, 180-day exclusivity, labeling, citizen petitions, and related drug-approval questions — along with experience before the ITC and the PTAB. His technical background is a B.S. in biology, which is consistent with the pharma/life-sciences docket rather than software, telecom/Wi-Fi, or mechanical matters; the available record shows no standard-essential-patent or wireless work.

Side preference. He works both sides. The tracked case data supplied for this profile records a single appearance on the defendant side, as lead counsel, but that list appears incomplete: the public docket shows him on generic-side defense teams (Hetero/Camber in Breckenridge Pharmaceutical v. Hetero, D. Del.; Dexcel Pharma against Pfizer) and on brand-side plaintiff teams (American Regent in the selenious-acid ANDA litigation, D.N.J.; Mallinckrodt in its Hatch-Waxman suit against Airgas). Patexia rankings cited in his firm bio place him in the top 100 most active ANDA attorneys both overall and for plaintiffs, and separately among the best-performing ANDA attorneys for defendants — a defendant-leaning but genuinely mixed practice concentrated in Hatch-Waxman, where the same firm often plays both roles.

Firm context. He is an associate in Sterne, Kessler, Goldstein & Fox P.L.L.C.'s Trial and Appellate Practice Group in Washington, D.C. He previously practiced at Axinn, Veltrop & Harkrider LLP in Hartford, Connecticut, in its intellectual property and FDA practice groups; court filings and PTAB papers from that period list him at Axinn and later at Sterne Kessler (2024 onward). He is not in-house.

Notable matters and PTAB. The most prominent verifiable results are team wins rather than individually credited lead results: Mallinckrodt Pharmaceuticals Ireland Ltd. v. Airgas Therapeutics LLC (D. Del. 1:22-cv-01648), where a Delaware jury returned a $9.5 million willful-infringement verdict in September 2025 (Alfano listed among associates on the Sterne Kessler team); and Dexcel Pharma v. Pfizer (D. Del.), a tafamidis/VYNDAMAX patent case resolved by settlement in April 2026 on the eve of bench trial, with Alfano listed as associate counsel. On the PTAB side, he was part of the Sterne Kessler team in SIG Sauer Inc. v. Lone Star Future Weapons, Inc., IPR2025-00410, which secured a June 2025 Acting Director decision denying institution; earlier, at Axinn, he was named back-up counsel on a KVK-Tech PTAB petition. This is secondary PTAB experience, not a practice built around frequent IPR/PGR first-chairing.

Bar and education. J.D., Fordham University School of Law; B.S., Biology, Quinnipiac University. Admitted in Connecticut, New York, and the District of Columbia; registered to practice before the USPTO (Reg. No. 74,298); admitted to the U.S. District Court for the District of Connecticut.

Note on identity: a Florida attorney named Alexander Joseph Alfano (J.D. 1993, financial/insurance practice) is a different person and is not the subject of this summary.